MyFinsight
Home
Blog
About
Proceeds from
convertible notes, net of...
$557,416K
Proceeds from exercise of
common stock options
$1,677K
(8285.00%↑ Y/Y)
Proceeds from employee
stock purchases
$798K
(215.42%↑ Y/Y)
Net cash provided by
financing activities
$422,874K
(7208.57%↑ Y/Y)
Canceled cashflow
$137,017K
Net change in cash
and cash...
$36,858K
(54.61%↑ Y/Y)
Canceled cashflow
$386,016K
Repayment of note payable
$137,017K
Proceeds from maturities
of investments
$115,000K
(-41.55%↓ Y/Y)
Loss on debt
extinguishment
-$11,477K
Other accrued
expenses
$11,436K
Stock-based compensation
$6,904K
(34.11%↑ Y/Y)
Prepaid clinical trial
costs
-$2,378K
Amortization of debt issuance
costs and discount
$1,214K
(11.58%↑ Y/Y)
Non-cash investment
(income) expense
-$332K
Payment-in-kind interest
$257K
(-48.70%↓ Y/Y)
Non-cash operating lease
expense
$65K
Depreciation
$59K
(-23.38%↓ Y/Y)
Net cash provided by
(used in) investing...
-$330,590K
(-466.84%↓ Y/Y)
Net cash used in
operating activities
-$55,426K
(23.09%↑ Y/Y)
Canceled cashflow
$115,000K
Canceled cashflow
$34,122K
Purchases of investments
$445,454K
(318.18%↑ Y/Y)
Net loss
-$78,864K
(4.13%↑ Y/Y)
Purchases of capitalized
software
$85K
Purchases of property and
equipment
$51K
(-48.48%↓ Y/Y)
Accrued license
milestone
$5,000K
Other current assets
$2,579K
(-50.89%↓ Y/Y)
Accounts payable
-$2,276K
(-223.70%↓ Y/Y)
Accrued clinical trial
costs
-$829K
Back
Back
Cash Flow
Celcuity Inc. (CELC)
Celcuity Inc. (CELC)
source: myfinsight.com